Pharmaceuticals & Biotech.
|
|
- Kristina Mariah Anderson
- 6 years ago
- Views:
Transcription
1 Sector Note July 14, 211 Overweight Company Rating TP (KRW) Green Cross BUY 215, Yuhan BUY 218, LG Life Sciences Hold 55, Daewoong Pharm. BUY 55, Hanmi Pharm Hold 98, Dong-A Pharm. BUY 151, Pharmaceuticals & Biotech. 2Q11F preview: Turnaround still slow but 2H11 outlook remains upbeat 2Q11 preview: Maintain Overweight as turnaround expected in 2H11; Green Cross is top pick Top six players in the KIS Universe pharmaceuticals sector should see sales stay flat (+.5% YoY) and OP lose 12.5% YoY in 2Q11F. Sales will be in line with the forecast but OP is set to miss our expectation and the consensus by 24%. Disappointing OP is attributed to: 1) drug price cuts following the government's incentives to hospitals for the purchase of low-priced drugs, and 2) heavier-thanexpected margin pressure from growing R&D investment. But sales and OP should increase 5.7% and 9.6%, respectively, from a quarter ago, supporting our hopes for a turnaround in 2H11. We reiterate Overweight on the sector. Our top pick is Green Cross, whose earnings and overseas momentum stands out among peers. Our TP is W215,, equal to 211F PE 23x. We also favor Dong-A Pharm on momentum from its new drug pipeline. Jung-In Lee jilee@truefriend.com Green Cross sees healthy sales growth while Hanmi continues to lose ground Following 1Q11, Green Cross sales growth topped the peers by jumping 15.4% YoY while Hanmi Pharm shed 13.4% YoY in 2Q11. Daewoong Pharm and Yuhan Corp. should increase 4.2% YoY and 2.5% YoY, respectively, as new products make up for sliding sales of existing products. But the operating accounts were sluggish overall. Although much anticipated, Green Cross OP should drop 6.9% YoY to W2bn, missing our forecast and the consensus by 13% and 36%, respectively. The lackluster operating results are due to: 1) slower-than-expected decline in the COGS for imported blood plasma after the acquisition of two blood centers, and 2) faster-than-expected progress of clinical trials abroad, resulting in a 11% YoY rise in R&D costs (with R&D costs-to-sales up 3.6%p YoY). Major subsidiaries: Yuhan Kimberly recovers from 1Q11 and Beijing Hanmi keeps prospering Sound earnings are expected at the subsidiaries Yuhan Kimberly and Beijing Hanmi. Putting an end to 1Q11 s sluggishness (sales up 3.7% YoY, OP down 27.5% YoY), Yuhan Kimberly should see sales and OP growth of 12.8% YoY and 22.8% YoY, respectively. By division, diaper sales should increase 6% YoY compared to -7.4% YoY in 1Q11, and sanitary napkins should grow 5% YoY on a 5.3% price increase. Beijing Hanmi should continue robust sales growth of 3% YoY in 2Q11 on full-fledged sales of 18 new products. Hopeful 2H11 turnaround: Higher outpatient prescription rate and more visible pipeline momentum Investor sentiment toward the pharmaceuticals sector is improving thanks to positive news such as deregulation to allow the sale of over-the-counter (OTC) drugs at supermarkets. If the top-tiers turn around and new drug pipeline momentum materializes in 2H11, the sector will have hit bottom and make an upturn (top-tiers sales growth -2.5% YoY in 1H vs. estimated 14.5% YoY in 2H). We are upbeat about the turnaround possibility considering: 1) more favorable operating environment for top-tiers in the wake of the introduction of dual-penalties j
2 for both rebate givers and takers, and 2) a spate of drug releases (generics in Jun and Yuhan s liver disease treatments worth W1bn in 4Q11). Our upbeat outlook is also bolstered by a steady improvement in the outpatient prescription rate (9.7% YoY in May and 5.8% YoY in Jun). Impressive overseas pipeline momentum in 2H11 is a boon for better sentiment among investors (Green Gross full-fledged flu vaccine exports to South America; Dong-A Pharm s completion of phase III clinical trials in the US for super-bacteria antibiotics; Hanmi Pharm s possible license-out of Labscovery, a sustained-release bio-manufacturing technology). 2Q11F earnings preview (W bn, %) KIS estimates Sales growth % OP growth % OP margin % % to Concensus % to old KIS estimates Sales OP QoQ YoY QoQ YoY Sales OP Sales OP Green Cross (6.9) (13.). (36.3) Dong-A (29.1) 12.2 (1.6) (11.3) (2.7) (15.1) Daewoong (23.) (29.4) 1.5 (2.3) (21.2) (2.8) (16.4) LG Life Sciences (12.4) (14.1) 11. (4.) (15.4) (2.9) (17.4) Yuhan (6.9) 39.5 (83.9) 2.2 (14.1) (69.5) (15.4) (53.) Hanmi (13.4) (11.1) (2.6) (1.) (3.5) Average (12.5) 2.9 (4.9) (25.2) (4.1) (23.6) Note: Ascending order by company s Sales growth YoY Source: Company data, Korea Investment & Securities Top 1 companies market share (%) Top Companies ranking 3th and lower Top-tier play ers regained some of its lost market shares since anti-rebate YTD Source: UBIST, Korea Investment & Securities 2
3 Pharmaceuticals valuation gap compared to MSCI Korea narrowed down to close a six-year historical low 211 annual health insurance financial deficit seems to recover : relieve from regulation risk 15 1 (%) +1 SD -1 SD Average Valuation premium over MSCI Korea 2, 1,5 1, (W bn) 1,79 1,568 1,179 1, (5) (75) (285) (3) Jan-4 Jan-5 Jan-6 Jan-7 Jan-8 Jan-9 Jan-1 Jan-11 (1,) (761) (882) -5 (1,5) (1,3) F Source: equant, Quantise, Company data, Korea Investment & Securities Note: Accumulated financial surplus of 971 billion Won in 211 May is due to company medical insurance payout Source: National Health Insurance Corporation, Ministry of Health & Welfare, Korea Investment & Securities Exports and overseas new drug pipeline developments Green Cross Yuhan Dong-A LG LS Hanmi Daewoong 1Q 2Q 3Q 4Q Flu vaccine clinical data Flu vaccine clinical trial results to be 1) Overseas blood 1) Flu vaccine exports submission to WHO PQ approved by WHO PQ derivatives M&A possibility to South America s PAHO 2) Green Gene-F 2) IVIG exports to (hemophilia) clinical trials to be Southeast Asia completed in China 1) Revanex exports to India 2) Liver disease medicine product introduced Zydena phase III clinical trial completion in US Domestic approval of new phyto-medicine(motilitone) 1) Labscovery Europe phase Submit application for II_a clinical trial completion Amosartan market release in Europe 2) Astra Zeneca lawsuit regarding Esomezol Source: Company data, Korea Investment & Securities Neuropathic pain-reliever enters phase II clinical trial 1) Zydena export to Brazil CT contrast medium release (August) 1) New phyto-medicine (Motilitone) release 2) KFDA approval of Medipost(Stem Cell Therapy) 3) Super Bacteria phase III clinical trial completion in US 1) SRH(infant) phase III clinical trial completion in US 2) DPP-4(diabetes) license-out possibility Labscovery license-out possibility 3
4 Peer valuation (W bn, %) Yuhan Hanmi Dong-A Greencross LG LS Daewoong Average Rating Buy Hold Buy Buy Hold Buy Share price(krw, 7/13) 14, 76,2 9,8 163,5 46,85 41,4 Target Price(KRW) 218, 98, 151, 215, 55, 55, Upside(%) MKT cap(krw bn) 1, ,191 1, PER 29A 13. (58.1) F F PBR 29A F F Sales growth(% YoY) 29A 3. (3.5) (6.9) F *(4.3) (.) F EPS growth(% YoY) 29A 1.8 NM (48.3) (2.3) 21F 15.9 NM 3.1 *(15.6) 25.9 * F OPM (%) 29A 12. (2.2) F F NPM (%) 29A 19.7 NM F F ROE (%) 29A F F ROA (%) 29A F F Note: 1. Greencross: Excluding influenza sales effect, 211 sales growth(2.8% YoY), EPS growth(15.7% YoY) 2. Daewoong: 211 EPS growth of 247.7% YoY is caused by a base effect of 28.4billion Won extra tax collection Source: Korea Investment & Securities 4
5 Changes to recommendation and price target Company (Code) Date Recommendation Price target Company (Code) Date Recommendation Price target Yuhan (1) BUY W24, BUY W215, BUY W218, LG Life Sciences NM W Dong-A Pharm BUY W135, (6887) BUY W88, (64) BUY W145, BUY W85, BUY W16, Hold W55, BUY W151, Daewoong Pharmaceutical Hold W65, Green Cross (628) BUY W165, (6962) BUY W55, BUY W25, Hanmi Pharm Hold W114, BUY W19, (12894) Hold W132, BUY W184, Hold W98, BUY W193, Yuhan(1) Dong-A Pharm.(64) 3, 25, 2, 15, 1, 5, Jul-9 Nov-9 Mar-1 Jul-1 Nov-1 Mar-11 Jul-11 Jul-9 Nov-9 Mar-1 Jul-1 Nov-1 Mar-11 18, 16, 14, 12, 1, 8, 6, 4, 2, Green Cross(628) LG Life Sciences(6887) 25, 2, 15, 1, 5, 1, 9, 8, 7, 6, 5, 4, 3, 2, 1, Jul-9 Nov-9 Mar-1 Jul-1 Nov-1 Mar-11 Jul-9 Nov-9 Mar-1 Jul-1 Nov-1 Mar-11 Daewoong Pharmaceutical(6962) Hanmi Pharm(12894) Jul-9 Nov-9 Mar-1 Jul-1 Nov-1 Mar-11 8, 7, 6, 5, 4, 3, 2, 1, Jul-9 Nov-9 Mar-1 Jul-1 Nov-1 Mar-11 14, 12, 1, 8, 6, 4, 2, 5
6 Guide to Korea Investment & Securities Co., Ltd. stock ratings based on absolute 12-month forward share price performance BUY: Expected to give a return of +15% or more Hold: Expected to give a return between -15% and +15% Underweight: Expected to give a return of -15% or less Guide to Korea Investment & Securities Co., Ltd. sector ratings for the next 12 months Overweight: Recommend increasing the sector s weighting in the portfolio compared to its respective weighting in the Kospi (Kosdaq) based on market capitalization. Neutral: Recommend maintaining the sector s weighting in the portfolio in line with its respective weighting in the Kospi (Kosdaq) based on market capitalization. Underweight: Recommend reducing the sector s weighting in the portfolio compared to its respective weighting in the Kospi (Kosdaq) based on market capitalization. Analyst Certification I/We, as the research analyst/analysts who prepared this report, do hereby certify that the views expressed in this research report accurately reflect my/our personal views about the subject securities and issuers discussed in this report. I/We do hereby also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this research report. Important Disclosures As of the end of the month immediately preceding the date of publication of the research report or the public appearance (or the end of the second most recent month if the publication date is less than 1 calendar days after the end of the most recent month), Korea Investment & Securities Co., Ltd., or its affiliates does not own 1% or more of any class of common equity securities of Yuhan. There is no actual, material conflict of interest of the research analyst or Korea Investment & Securities Co., Ltd., or its affiliates known at the time of publication of the research report or at the time of the public appearance. Korea Investment & Securities Co., Ltd., or its affiliates has not managed or co-managed a public offering of securities for Yuhan in the past 12 months; Korea Investment & Securities Co., Ltd., or its affiliates has not received compensation for investment banking services from Yuhan in the past 12 months; Korea Investment & Securities Co., Ltd., or its affiliates does not expect to receive or intends to seek compensation for investment banking services from Yuhan in the next 3 months. Korea Investment & Securities Co., Ltd., or its affiliates was not making a market in Yuhan s securities at the time that the research report was published. Korea Investment & Securities Co., Ltd. does not own over 1% of Yuhan,Dong-A Pharm.,Green Cross,LG Life Sciences,Daewoong Pharmaceutical,Hanmi Pharm shares as of July 15, 211. Korea Investment & Securities Co., Ltd. has not provided this report to various third parties. Neither the analysts covering these companies nor their associates own any shares of as of July 15, 211. Prepared by: Jung-In Lee This report was written by Korea Investment & Securities Co., Ltd. to help its clients invest in securities. This material is copyrighted and may not be copied, redistributed, forwarded or altered in any way without the consent of Korea Investment & Securities Co., Ltd. This report has been prepared by Korea Investment & Securities Co., Ltd. and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy. We make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no liability whatsoever for any direct or consequential loss arising from any use of this report or its contents. The final investment decision is based on the client s judgment, and this report cannot be used as evidence in any legal dispute related to investment decisions. 6
Pharmaceuticals & Biotech
j Sector Note March 18, 211 Overweight Company Rating TP (KRW) Daewoong Pharm. BUY 55, Hanmi Pharm Hold 98, Yuhan BUY 218, Dong-A Pharm. BUY 151, Green Cross BUY 184, LG Life Sciences Hold 55, Pharmaceuticals
More informationDaewoong Pharmaceutical (069620)
Earnings Review July 31, 2014 12M rating BUY (Maintain) 12M TP W85,000 from W85,000 Up/downside +44% Stock Data KOSPI (Jul 30, pt) 2,083 Stock price (Jul 30, KRW) 58,900 Market cap (USD mn) 666 Shares
More informationFila Korea (081660) Widespread growth potential
Fila Korea (8166) BUY (Maintain), TP: W98, (Maintain) Stock price (Apr 26, KRW) 83,5 Yr to Sales OP EBT NP EPS % chg EBITDA P/E EV/EBITDA P/B ROE Market cap (USD mn) 697 Dec (W bn) (W bn) (W bn) (W bn)
More informationCosmax (192820) Company Note. Smooth transition, third growth phase. BUY (Initiate)
Company Note April 7, 2014 (192820) 12M rating BUY (Initiate) 12M TP W75,000 Up/downside +23% Stock Data(Pre-separation data) KOSPI (Apr 4, pt) 1,988 Stock (Apr 4, KRW) 60,000 Market cap (USD mn) 774 Shares
More informationKorea Zinc (010130) Company Note. 1Q12 preview: Not over until it s over. BUY (Maintain)
Company Note April 1, 212 Korea Zinc (113) 12M rating BUY (Maintain) 12M TP W6, from W6, Up/downside +57% Stock Data KOSPI (Apr 9, pt) 1,997 Stock price (Apr 9, KRW) 381,5 Market cap (USD mn) 6,286 Shares
More informationYG Entertainment (122870)
Company Note August 29, 212 12M rating BUY (Maintain) 12M TP W69, from W69, Up/downside +11% Stock Data KOSPI (Aug 28, pt) 1,916 Stock price (Aug 28, KRW) 62,2 Market cap (USD mn) 561 Shares outstanding
More informationSemiconductor equipment
Sector Note February 18, 214 Semiconductor equipment Overweight Objective view on 3D NAND investment Company Rating TP (KRW) Eugene Technology BUY 28, Wonik IPS BUY 11,5 Semiconductor equipment shares
More informationDuksan Hi-Metal (077360)
Company Note March 14, 2014 Duksan Hi-Metal (077360) 12M rating BUY (Maintain) 12M TP W24,000 from W24,000 Up/downside +32% Stock Data KOSPI (Mar 13, pt) 1,934 Stock price (Mar 13, KRW) 18,250 Market cap
More informationLG Innotek (011070) Company Note. Concerns unjustified, 3Q14 results to beat consensus. BUY (Maintain)
Company Note August 29, 214 LG Innotek (117) 12M rating BUY (Maintain) 12M TP W17, from W17, Up/downside +29% Stock Data KOSPI (Aug 28, pt) 2,76 Stock price (Aug 28, KRW) 132, Market cap (USD mn) 3,22
More informationCrucialTec (114120) BUY (Maintain) Company Note. Robust growth to continue. TP: W70,000 (Up)
Company Note February 22, 2011 CrucialTec (114120) BUY (Maintain) TP: W70,000 (Up) KOSPI (Feb 21) 2,005 Stock price (Feb 21) 46,300 Shares outstanding (mn) 8.4 Market cap (USD mn) 349 52-Week Low/High
More informationS-Oil (010950) Healthier revenue structure already reflected in valuations
S-Oil (010950) Hold (Initiate) Stock price (Sep 15, KRW) 46,000 Market cap (USD mn) 4,989 Shares outstanding (mn) 113 52W High/Low (KRW) 81,200/43,500 6M avg. daily turnover (USD mn) 15.4 Free float (%)
More informationDongsung Finetec (033500)
Earnings Review November 15, 213 12M rating BUY (Maintain) 12M TP W13, from W13, Dongsung Finetec (335) Full-bore turnaround Above In line Below Up/downside +2% Stock Data KOSPI (Nov 14, pt) 1,968 Stock
More informationHyundai Steel (004020)
Earnings Review February 1, 213 12M rating BUY (Maintain) 12M TP W111, from W111, Hyundai Steel (42) Astonishing earnings in many aspects Above In line Below Up/downside +34% Stock Data KOSPI (Jan 31,
More informationSilicon Works (108320)
Company Note June 8, 2018 12M rating BUY (Maintain) OLED growth starts with Silicon Works 12M TP W56,000 Up/downside +38% from W56,000 2Q18 OP to surge 165% YoY to W8.4bn Despite disappointing 1Q18 results,
More informationDaewoong Pharmaceutical ( KS)
June 11, 214 (6962 KS) Shares and earnings touch bottom BUY (UPGRADE) Price (Jun. 1) W58,8 Target Price W74, % variance 25.9% KiDal Bae (82-2) 3772-1554 kdbae@shinhan.com EungHyun Kim (82-2) 3772-1568
More informationSilicon Works (108320)
Earnings Review August 14, 2017 12M rating BUY (Maintain) 12M TP W50,000 from W50,000 Up/downside +44% Stock Data KOSPI (Aug 11, pt) 2,320 Stock price (Aug 11, KRW) 34,700 Market cap (USD mn) 494 Shares
More informationYG Entertainment (122870)
Company Note February 23, 2017 YG Entertainment (122870) 12M rating Value Stock Data Hold (Downgrade) Growth Turn around Issue KOSPI (Feb 22, pt) 2,107 Stock price (Feb 22, KRW) 27,850 Market cap (USD
More informationLotte Confectionery (004990)
Company Note May 9, 211 Lotte Confectionery (499) BUY (Maintain) TP: W2,, (Up) KOSPI (May 6) 2,147 Stock price (May 6) 1,67, Shares outstanding (mn) 1.4 Market cap (USD mn) 2,19 52-Week Low/High (won)
More informationHalla Visteon Climate Control (018880)
Halla Visteon Climate Control (1888) Hold (Reinstate) Stock price (Mar 31, KRW) 48,6 Market cap (USD mn) 4,873 Shares outstanding (mn) 17 52W High/Low (KRW) 48,6/27,2 6M avg. daily turnover (USD mn) 6.8
More informationDaewoo E&C (047040) Company Note. Asia conference feedback; Contrarian thinking
Company Note February 10, 2012 Daewoo E&C (047040) 12M rating BUY (Maintain) 12M TP W17,000 from W17,000 Up/downside +45% Stock Data KOSPI (Feb 8, pt) 2,004 Stock price (Feb 8, KRW) 11,750 Market cap (USD
More informationSamsung C&T (000830)
Company Comment March 29, 2013 Samsung C&T (000830) BUY TP W97,000 Stock(Mar 28) W68,500 Wins Australia s Roy Hill project; previous bidding system no longer valid News: Samsung C&T wins W6.5trn mine project
More informationKorean Air (003490) Company Note. Timely relisting. Hold (Maintain)
Company Note September 16, 2013 12M rating Hold (Maintain) Timely relisting Stock Data KOSPI (Sep 13, pt) 1,994 Stock price (Sep 13, KRW) 28,200 Market cap (USD mn) 1,890 Shares outstanding (mn) 59 52-Week
More informationVieworks (100120) Earnings Review. Competitiveness to sustain growth. BUY (Maintain)
Earnings Review August 21, 214 12M rating BUY (Maintain) 12M TP W39, from W34, Up/downside +27% Stock Data KOSPI (Aug 2, pt) 2,73 Stock price (Aug 2, KRW) 3,8 Market cap (USD mn) 38 Shares outstanding
More informationNew merchandise to prop up results
Korea/Pharmaceuticals Daewoong Pharmaceutical Earnings preview BUY 12 July 2010 BUY BUY BUY 4 May 2010 16 Apr 2010 23 Mar 2010 Ji-Won Shin, Korea Pharmaceuticals Analyst, +82 2 3774 2176 jwshin@miraeasset.com
More informationWonik Materials (104830)
Company Note July 17, 213 Wonik Materials (1483) 12M rating BUY (Maintain) 12M TP W52, from W44, Up/downside +44% Stock Data KOSPI (Jul 16, pt) 1,866 Stock price (Jul 16, KRW) 36,1 Market cap (USD mn)
More informationSM Entertainment (041510)
Company Note October 21, 213 SM Entertainment (4151) 12M rating BUY (Maintain) 12M TP W54, from W54, Up/downside +45% Stock Data KOSPI (Oct 18, pt) 2,52 Stock price (Oct 18, KRW) 37,3 Market cap (USD mn)
More informationHyundai Wia (011210)
Hyundai Wia (011210) BUY (Reinstate), TP: W206,000 Stock price (Mar 31, KRW) 171,000 Market cap (USD mn) 4,132 Shares outstanding (mn) 26 52W High/Low (KRW) 199,500/127,000 6M avg. daily turnover (USD
More informationEarnings to stay on growth trajectory
1 November 214 (3671 KS) Earnings to stay on growth trajectory BUY (MAINTAIN) Price (Nov 7) W1,5 Target Price W13, % variance 29.4% YoungChan Kim (82-2) 3772-1595 youngkim@shinhan.com KOSPI 1,939.87p KOSDAQ
More informationDonga ST (170900) Company Visit Note. BUY (Maintain)
June 24, 2013 Donga ST (170900) Positive Neutral Negative 12M rating BUY (Maintain) 12M TP W235,000 from W235,000 Up/downside +111% Stock Data KOSPI (Jun 21, pt) 1,823 Stock price (Jun 21, KRW) 111,500
More informationLG International ( KS)
April 15, 214 (112 KS) Clearer visibility on long-term earnings growth BUY (MAINTAIN) Price (Apr. 14) W3,15 Target Price W38, % variance 26.% MinHo Hur (82-2) 3772-2183 hiroo79@shinhan.com KOSPI 1,997.2p
More informationDong-A Pharmaceutical ( KS)
Dong-A Pharmaceutical (64 KS) Trading Buy (Initiate) Target Price (12M, W) 115, Share Price (9/3/12, W) 94,6 Expected Return (%) 21.6 EPS Growth (12F, %) -3.7 Market EPS Growth (12F, %) 12.7 P/E (12F,
More informationMando (060980) BUY. Company Comment. Solution to corporate governance problem
Company Comment April 8, 2014 (060980) BUY TP W184,000 Stock (Apr 7) W135,000 Solution to corporate governance problem To adopt holding company structure via spin-off On April 7, announced it would execute
More informationLG Innotek ( KS)
Company Report Apr 6, 215 LG Innotek (117 KS) With uncertainties priced in, time to shed light on positives Electronics/parts BUY (M) TP: W135, (M) Share price (won, Apr 3) 11,5 Paid-in capital (Wbn) 118
More informationPER EV/EBITDA PBR ROE
December 19, 213 (3671 KS) Focus on turnaround in 214 BUY (UPGRADE) Price (Dec. 18) W6,38 Target Price W8, % variance 25.4% YoungChan (82-2) 3772-1595 Kim youngkim@shinhan.com KOSPI 1,974.63p KOSDAQ 485.65p
More informationSilicon Works ( KS)
January 18, 217 (1832 KS) 4Q16 preview: Better than expected BUY (MAINTAIN) Price (Jan. 17) W3,4 Target Price W36, % variance 2.% YoungSik Yoon (82-2) 3772-153 youngsik.yoon@shinhan.com JoonDoo Ha (82-2)
More informationSimmtech ( KS)
Sep 7, 218 Electronics/parts DRAM upgrade begins 2H18 earnings likely to turn around strongly, with OP estimated at W31.5bn Rating Target price BUY (M) W21,6 (M) Current price (Sep 4) W9,51 Upside potential
More informationElectronics/parts. Longer-term approach to smartphone part makers. Electronics/parts: 4Q14 preview
Sector Report Jan 13, 215 Longer-term approach to smartphone part makers (OVERWEIGHT) Company Rating TP SEC BUY (M) 1,47, (M) SEMCO BUY (M) 69, (M) LGE BUY (M) 85, (M) LG Innotek BUY (M) 128, (M) KH Vatec
More informationSUMMARY FINANCIAL DATA
Company Initiation (28513) Vaccines set to go global We reinstate coverage of at BUY with a KRW1, target. The company will likely benefit from its recent co-polyester plant capacity additions and subsequent
More informationValuation. Economic forecast
November 13, 2013 Market Performance Nov 13 1D 1M 3M YTD KOSPI (pt) 1,963.56 (1.60) (3.03) 2.64 (1.68) Turnover (W bn) 3,340 KOSDAQ (pt) 505.60 (1.00) (5.07) (8.21) 1.87 Major Indicators Nov 12 1-wk ago
More informationHankook Tire ( KS)
June 11, 214 (16139 KS) Global top 3 for profitability BUY (MAINTAIN) Price (Jun. 1) W64,2 Target Price W78, % variance 21.5% Eric Choi (82-2) 3772-1552 eric.choi@shinhan.com KOSPI 2,11.8p KOSDAQ 532.64p
More informationHugel (145020) Earnings Review. Record earnings but concerns over botulinum toxin strain origins
Earnings Review October 27, 216 12M rating BUY (Maintain) 12M TP W615, from W615, Up/downside +84% Stock Data KOSPI (Oct 26, pt) 2,14 Stock price (Oct 26, KRW) 334,1 Market cap (USD mn) 968 Shares outstanding
More informationGS E&C (006360) Earnings Review
Earnings Review April 30, 2014 GS E&C (006360) Above In line Below 12M rating Hold (Maintain) Earnings direction shifts, now focus on recovery pace Stock Data KOSPI (Apr 29, pt) 1,965 Stock price (Apr
More informationCheil Industries (028260)
Company Note May 27, 2015 Cheil Industries (028260) 12M rating BUY (Maintain) 12M TP W255,000 from W200,000 Up/downside +36% Stock Data KOSPI (May 26, pt) 2,144 Stock price (May 26, KRW) 188,000 Market
More informationPER EV/EBITDA PBR ROE
4 January 2018 (004800 KS) Valuation discount to dissipate on holdco conversion BUY (MAINTAIN) Price (Jan 3) W147,500 Target Price W180,000 % variance 22.0% Eung-Ju Lee (82-2) 3772-1559 eungju.lee@shinhan.com
More informationHyundai Mipo Dockyard (010620)
Hyundai Mipo Dockyard (010620) Company Brief / Shipbuilding & Machinery April 19, 2010 BUY (Maintain) Price target (12M): W190,000 Stock Data KOSPI (Apr 15) 1,744 Stock price (Apr 15, won) 154,000 Shares
More informationCoway ( KS) Good start to China water-purifier market entry. Korea Research KRW121,000 KRW103,000. Event. Impact. Action and recommendation
Korea Research This research report is a product of (Korea) Flashnote Korea / Consumer 1 June 2016 BUY Target price Last price (31 May 2016) KRW121,000 KRW103,000 Upside/downside (%) 17.5 KOSPI 1,983.40
More informationSK Innovation (096770)
SK Innovation (096770) Hold (Initiate) Stock price (Oct 8, KRW) 146,000 Market cap (USD mn) 12,573 Shares outstanding (mn) 92 52W High/Low (KRW) 182,000/128,500 6M avg. daily turnover (USD mn) 44.3 Free
More informationHyundai E&C ( KS)
Company Report (72 KS) Construction OP margin to bottom in 2Q but pick up in Q Maintain Buy call with TP of W15, We maintain our Buy call on with a target price of W15,. The company received overseas orders
More informationSimmtech (222800) Focus on 2H earnings WHAT S THE STORY?
Company Update Simmtech (222800) Focus on 2H earnings Simmtech yesterday reported disappointing 4Q results, which compels us to cut our 2018 operating profit forecast by 10% to KRW52.9b and 12-month target
More informationSK Telecom ( KS)
Company Report Mar 13, 215 SK Telecom (1767 KS) Possible scenario for SK Group telecom subsidiary restructuring Telecom services BUY (M) TP: W38, (M) Share price (won, Mar 12) 27, Paid-in capital (Wbn)
More informationHotel Shilla ( KS)
Company Report Nov 16, 215 Hotel Shilla (877 KS) Our take on Seoul, Busan downtown duty-free license awards Retail/leisure BUY (M) TP: W153, (D) Share price (won, Nov 13) 13, Paid-in capital (Wbn) 2 Market
More informationLotte Hi-Mart ( KS)
(071840 KS) Margins to improve in 2H Retail Results Comment May 12, 2014 (Maintain) Buy Target Price (12M, W) 89,000 Share Price (5/9/14, W) 72,300 Expected Return 23% OP (, Wbn) 187 Consensus OP (, Wbn)
More informationCJ CGV (079160) Company Note. China site visit: Rapid growth confirmed. BUY (Maintain)
Company Note September 30, 2013 12M rating BUY (Maintain) CJ CGV (079160) China site visit: Rapid growth confirmed 12M TP W70,000 from W70,000 Up/downside +23% Stock Data KOSPI (Sep 27, pt) 2,012 Stock
More informationLG Innotek ( KS)
(117 KS) Coming out with flying colors Technology Results Comment (Maintain) Buy Target Price (12M, W) 14, Share Price (1/27/15, W) 17, Expected Return 31% OP (14F, Wbn) 314 Consensus OP (14F, Wbn) 319
More informationHanssem (009240) Market consolidation begins
Hanssem (924) BUY (Initiate), TP W133, Stock price (Aug 23, KRW) 18, Market cap (USD mn) 2,541 Shares outstanding (mn) 23.5 52W High/Low (KRW) 18,/34,5 6M avg. daily turnover (USD mn) 6.6 Free float (%)
More informationHite Jinro ( KS)
(8 KS) It s always darkest before the dawn Beverage Company Report April 1, 213 (Maintain) Trading Buy Target Price (12M, W) 37, Share Price (3/29/13, W) 33,85 Expected Return 9% OP (13F, Wbn) 192 Consensus
More informationInstitutional Equities
4QFY18 Result Update Institutional Equities Atul Auto 30 May 2018 Reuters: ATUL.BO; Bloomberg: ATUL IN Higher Expenses Mar Profitability Atul Auto s (AAL) 4QFY18 earnings missed our expectations on account
More informationMaruti Suzuki (RHS) BUY. Operationally In Line; Reiterate Buy. Automobiles October 31, 2014 RESULT REVIEW. Outlook & Valuation.
Oct13 Dec13 Jan14 Feb14 Apr14 May14 Jun14 Aug14 Sep14 Oct14 India Research Automobiles RESULT REVIEW Bloomberg: MSIL IN Reuters: MRTI.BO BUY Operationally In Line; Reiterate Buy India s (MSIL) Revenue/EBIDTA/PAT
More informationHanmi Pharmaceutical ( KS)
Hanmi Pharmaceutical (128940 KS) Buy (Initiate) Target Price (12M, W) 110,000 Share Price (09/03/12, W) 83,600 Expected Return (%) 31.6 EPS Growth (12F, %) 393.5 Market EPS Growth (12F, %) 12.7 P/E (12F,
More informationSIEMENS INDIA LIMITED RESEARCH
RESULTS REVIEW Siemens India Limited Hold Share Data Market Cap Rs. 196.1 bn Price Rs. 581.6 BSE Sensex 14,961.07 Reuters Bloomberg Avg. Volume (52 Week) SIEM.BO SIEM IN 0.2 mn 52-Week High/Low Rs. 1,142.5
More informationLuk Fook (590 HK) Strong 1Q gem-set SSS in China. Core profit (HK$ m) Net profit (HK$ m) Turnover (HK$ m)
Equity Research Consumer Discretionary Luk Fook (590 HK) Hold (maintained) Target price: HK$23.10 Strong 1Q gem-set SSS in China China gem-set SSS outperformed CTF SSS in China improved from -5% in 1QFY15
More informationLuk Fook (590 HK) Hold (downgraded) Target price: HK$ HFY18 results beat, but downgrade from Accumulate to Hold on rich valuation
Equity Research Consumer Discretionary Luk Fook (590 HK) Hold (downgraded) Target price: HK$34.80 Albert Yip, CFA SFC CE No. ADT599 albertyip@gfgroup.com.hk +852 3719 1010 GF Securities (Hong Kong) Brokerage
More informationBupa Arabia for Cooperative Insurance Co. Insurance BUPA ARABIA 8210.SE
Jan-17 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Bupa Arabia for Cooperative Insurance Co. Recommendation Overweight Current Price (SAR) 91.95 Target Price (SAR)
More informationi-sens (099190) Not rated Small-cap Company Note July 3, 2014 Growth potential stemming from a high-quality customer base
Small-cap Company Note July 3, 214 i-sens (9919) Not rated Stock Data KOSPI (Jul 2, pt) 2,15 Stock price (Jul 2, KRW) 53,1 Market cap (USD mn) 476 Shares outstanding (mn) 9 52-Week high/low (KRW) 58,4/33,6
More informationLG International (001120) Poor 3Q expected to be just a blip WHAT S THE STORY? SUMMARY OF 3Q RESULTS
Company Update LG International (112) Poor 3Q expected to be just a blip Jaeseung Baek Analyst jaeseung.baek@samsung.com 822 22 7794 LG International (LGI) yesterday reported that its consolidated sales
More informationHankook Tire ( KS)
(16139 KS) Aggressive expansion to enhance global presence Auto Results Comment October 29, 213 (Maintain) Buy Target Price (12M, W) 78, Share Price (1/28/13, W) 65,4 Expected Return 19% OP (13F, Wbn)
More informationGreen Cross ( KS)
(006280 KS) Improving visibility on overseas expansion Healthcare Event Summary November 23, 2015 (Maintain) Buy Target Price (12M, W) 252,000 Share Price (11/20/15, W) 194,500 Expected Return 30% OP (15F,
More informationPTC India Financial Services
India I Equities BFSI Result Update Change in Estimates Target Reco 2 January 215 PTC India Financial Services Improving sanctions, high NIM, stable asset quality; Buy Key takeaways Strong loan growth,
More informationHyundai Wia (IPO) Another Mobis is coming BUY (Initiate)
Hyundai Wia (IPO) Company Brief / Autos February 7, 211 Another Mobis is coming BUY (Initiate) Price target (12M): W85, Stock Data KOSPI (Feb 1) 2,72.3 IPO stock price (won) 65, Shares outstanding (mn)
More informationTCL Communication (2618 HK) Painful transition period. Buy (Maintain) Target Price HK$2.33 Up/downside +28.5% Current price HK$1.
Securities Analysis (Equity) TCL Communication (218 HK) Painful transition period 1H12 profit warning. TCL Com announced profit warning on 15 Jul and expected to record a significant drop in 2Q12 net profit
More informationThe Company for Cooperative Insurance Insurance TAWUNIYA AB 8010.SE
Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 Recommendation Overweight Current Price (SAR) 82.60 Target Price (SAR) 101.13 Upside/Downside (%) 22.4% As of
More informationFILA Korea (081660) Company Note. NDR takeaways: Collective efforts fuel brand power. BUY (Maintain)
Company Note November 20, 2013 FILA Korea (081660) 12M rating BUY (Maintain) 12M TP W100,000 from W100,000 Up/downside +28% Stock Data KOSPI (Nov 19, pt) 2,032 Stock price (Nov 19, KRW) 78,300 Market cap
More informationColgate-Palmolive (India)
Result Update Colgate-Palmolive (India) 27 July 218 Reuters: COLG.BO; Bloomberg: CLGT IN Tough Times Continue Colgate-Palmolive (India) or CLGT reported a mixed earnings performance in. Volume and revenue
More informationNational Industrialization Co. Diversified Operations Industrial NIC AB: Saudi Arabia 25 May 2014
RSI10 National Industrialization Co. NIC AB: Saudi Arabia 25 May 2014 Rating Target price Current price OVERWEIGHT SAR37.30 (18.7% upside) SAR31.40 Key themes & implications Sluggish petrochemical prices
More informationBHARAT HEAVY ELECTRICALS LIMITED RESEARCH
RESULTS REVIEW Bharat Heavy Electricals Limited Hold Share Data Market Cap Rs. 779.4 bn Price Rs. 1,592.10 BSE Sensex 13,791.54 Reuters BHEL.BO Bloomberg BHEL IN Avg. Volume (52 Week) 0.26 mn 52-Week High/Low
More informationHyundai E&C (000720)
Earnings Review January 27, 2014 12M rating BUY (Maintain) 12M TP W75,000 from W75,000 Hyundai E&C (000720) Steady earnings despite hard times Above In line Below Up/downside +28% Stock Data KOSPI (Jan
More informationJamna Auto Industries
2QFY19 Result Update Institutional Equities Jamna Auto Industries Reuters: JMNA.NS; Bloomberg: JMNA IN Performance Below Expectations; Retain Buy Due To Strong Outlook Jamna Auto s 2QFY19 earnings were
More informationKOLAO Holdings ( KS)
Company Report (900140 KS) Retail New businesses need to deliver 1Q12 Review: Record earnings and stronger-than-expected margins Based on 1Q preliminary results, continued to set record earnings with revenues
More informationKWG. Seeking balance between scale and profitability. March 27, 2018 Equity Research. Stock code: 1813.HK Rating: HOLD Price target (HK$) 12.
Equity Research Seeking balance between scale and profitability Downgrade to HOLD and revise down TP to HK$12.50: 2017 result missed our estimation; core net profit dropped by 19% YoY, expansion execution
More informationKalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256
: price: EPS: How does our one year outlook change? We expect KPP s revenue (standalone) to grow by 21% y-o-y in FY17E backed by an order book of Rs. 91bn (1.7x FY17E book-to-bill). Both Transmission line
More informationQuarterly results (YE Mar) 2QFY14 2QFY15 % yoy H1FY14 H1FY15 % yoy
India I Equities Healthcare Result Update 3 November 2014 Granules India Strong performance, margin improvement to sustain; Buy Rating: Buy Target Price: `1,185 Share Price: `807 Key takeaways Strong quarter.
More informationCMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133
4QFY17 Result Update June 06, 2017 Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133 Mixed Quarterly Performance; Volume to Remain Strong has reported a mixed performance in 4QFY17. Its blended
More informationKarur Vysya Bank (KVB) KVB IN; KVB.BO
Banking India (KVB) KVB IN; KVB.BO Institutional Equity Research May 2, 2015 result review HOLD Consolidating growth, high capital, elevated slippages Current price (30 Apr) Rs 482 Target price Rs 560
More informationHong Kong Economy: Recovering from Recession?
Irina Fan Senior Economist irinafan@hangseng.com Joanne Yim Chief Economist joanneyim@hangseng.com September 29 Hong Kong Economy: Recovering from Recession? Hong Kong staged a strong rebound in the second
More informationCR Lands. Winner of next 5 years, BUY. March 21, 2018 Equity Research. Stock code: 1109.HK Rating: BUY Price target (HK$) 34.74
Equity Research Winner of next 5 years, BUY 2017 result: slow growth, but high profitability Revenue slightly improved by 8.5% YoY to HKD 118.5 bn. Thanks to GPM growing by 6.5 pts to 40%, gross profit
More informationExide Industries BUY. Auto Components February 03, Volume Recovery & Cost Saving to Cushion Margins RESULT UPDATE
Feb-14 Mar-14 Apr-14 Jun-14 Jul-14 Aug-14 Oct-14 Nov-14 Dec-14 Jan-15 Institutional Equities India Research Auto Components February 03, 2015 RESULT UPDATE Bloomberg: EXID IN Reuters: EXID.BO BUY Volume
More informationStandalone Quarterly results (YE Mar) 1QFY14 1QFY15 % yoy FY13 FY14 % yoy
India I Equities Healthcare Result Update 15 July 2014 Unichem Laboratories Recovery in sight; Buy Key takeaways Results slightly above our estimates. Unichem Laboratories (Unichem) revenue grew 9.6% yoy,
More informationMacrogen ( KQ)
(038290 KQ) High-margin overseas operations have just begun Bio Results Comment May 29, 2013 (Maintain) Buy Target Price (12M, W) 55,000 Share Price (05/28/13, W) 39,250 Expected Return 40% OP (13F, Wbn)
More informationDaewoo E&C ( KS) WHAT S THE STORY?
Company Update (047040 KS) All-round margin improvements WHAT S THE STORY? Event: yesterday after market close reported that its parentbased operating profit hit KRW107.6b in 3Q, vs the consolidated consensus
More informationEquity Research
Equity Research research@armsecurities.com.ng +234 1 270 1652 7 November 2016 Flour Mills of Nigeria Plc Earnings Report 6 months ended 30 th September, 2016 Price hikes offset input cost pressures (NEUTRAL:
More informationSM Entertainment ( KQ)
Company Report (041510 KQ) Entertainment Rosy earnings outlook for 2Q and beyond Trim TP to W57,400 to reflect EPS dilution; Maintain Buy call We maintain our Buy call on. Although we trim our target price
More informationGuotai Junan International [1788.HK]
Guotai Junan International [788.HK] Adjustment of Margin Financing Business Largely Completed; Reiterate BUY Net profit of Guotai Junan International (GTJAI) was HK$.bn for 7, up 7% YoY. This was lower
More informationMarket Access. M&A Securities. Results Review 1Q15. Malayan Banking Bhd BUY (TP: RM10.70) Stabilizing Period. Results Review
M&A Securities Results Review 1Q15 PP14767/09/2012(030761) Malayan Banking Bhd BUY (TP: RM10.70) Friday, May 29, 2015 Stabilizing Period Results Review Actual vs. expectation. Malayan Banking Berhad (Maybank)
More informationLAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Boston EQUITY RESEARCH Company Report Alimera Sciences (ALIM - $1.80) Iluvien sales continue their slow & steady growth ALIM reported 1Q16 roughly in-line
More informationJuhayna Food Industries
Flashnote MENA research Another disappointing quarter 1Q12 results disappoint despite sturdy top line growth, mainly on base effects Easing commodity prices and product price increases to help alleviate
More informationCMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245
3QFY18 Result Update February 05, 2018 CMP* (Rs) 166 Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245 Wage Provisioning, Lower in Plant Availability Impede Earnings Growth has delivered
More informationKC Tech ( KS) CMP slurry market share to increase. Display. Buy (Maintain) Raise TP by 9% to W12,000 (vs. current share price of W7,560)
March 21, 211 (2946 KS) Korea-Equity Research Display Jonathan Hwang +822-768-414 j.hwang@dwsec.com Brian Oh +822-768-4135 brian.oh@dwsec.com CMP slurry market share to increase Raise TP by 9% to W12,
More informationCJ CGV ( KS) Strong popularity of Masquerade likely to drive 4Q earnings. Entertainment. November 1, 2012 Company Report.
Company Report (079160 KS) Entertainment Strong popularity of Masquerade likely to drive 4Q earnings Chinese and Vietnamese movie markets expected to grow rapidly According to PricewaterhouseCoopers (PwC),
More informationMegastudy (072870/BUY )
(7287/BUY ) RESULTS NOTE 3Q numbers down y-y but in line with estimates Target price KRW2, Upside/downside +19.8% Current price KRW166,9 3Q earnings disappoint on weak high school online division performance
More informationNoibai Cargo Terminal Services JSC (NCT: HOSE)
Noibai Cargo Terminal Services JSC (NCT: HOSE) BUY 1Y Price Target: VND 129,600 Current price: VND 98,000 Giang Hoang Nguyen giangnh@ssi.com.vn +84-24 3936 6321 ext. 676 30 November 2017 INDUSTRIALS- VIETNAM
More information